Biotechnology

Anbio Biotechnology

Anbio Biotechnology released FY2025 Q4 earnings on April 7 (EST), actual revenue USD 2.031 M, actual EPS USD 0.0296

Anbio Biotechnology released FY2025 Q3 earnings on April 7 Post-Market (EST), actual revenue USD 2.031 M, actual EPS USD 0.0296

Anbio Biotechnology released FY2025 earnings on April 7 (EST), actual revenue USD 8.647 M, actual EPS USD 0.1466

Anbio Biotechnology released FY2025 9 Months Earnings on April 7, 2026 (EST), with actual revenue of USD 6.616 M and actual EPS of USD 0.117

Anbio Biotechnology released FY2025 Q2 earnings on December 30 (EST), actual revenue USD 2.292 M, actual EPS USD 0.0435

Anbio Biotechnology released FY2025 Q1 earnings on December 30 (EST), actual revenue USD 2.292 M, actual EPS USD 0.0437

Anbio Biotechnology released FY2025 Semi-Annual Earnings on December 30 (EST), actual revenue USD 4.585M, actual EPS USD 0.0874

Anbior Biotech to Attend Three Major International Exhibitions

Anbio Biotechnology released FY2024 Annual Earnings on April 28 (EST), with actual revenue of USD 8.185 M and EPS of USD 0.0561

Anbio Biotechnology released FY2024 Q3 earnings on April 28 (EST), actual revenue USD 1.168 M, actual EPS USD -0.0144

Anbio Biotechnology released FY2024 Q4 earnings on April 28 (EST), actual revenue USD 1.168 M, actual EPS USD -0.0144

Anbio Biotechnology released FY2024 9 Months Earnings on April 28, 2025 EST, with actual revenue of USD 7.017 M and EPS of USD 0.0705

Anbio Biotechnology released FY2023 Q3 earnings on January 10, 2025 (EST), with actual revenue of USD 1.826 M and EPS of USD 0.0086

Anbio Biotechnology released FY2022 annual earnings on January 10, 2025 (EST), with actual revenue of 23.54 M USD and EPS of 0 USD

Anbio Biotechnology released FY2023 Annual Earnings on January 10, 2025 (EST) with actual revenue of USD 6.712 M and EPS of USD 0.1051

Anbio Biotechnology released FY2023 Q4 earnings on January 10, 2025 (EST) with actual revenue of USD 1.826 M and EPS of USD 0.0086

Anbio Biotechnology released FY2022 Q4 earnings on January 10, 2025 (EST) with actual revenue of 2.852 M USD and EPS of 0 USD

Anbio Biotechnology released FY2022 9 Months Earnings on January 10, 2025 (EST) with actual revenue of 20.69 M USD and EPS of 0 USD

Anbio Biotechnology released FY2022 Q3 earnings on January 10, 2025 (EST) with actual revenue of 2.852 M USD and EPS of 0 USD

Anbio Biotechnology released FY2023 9 Months Earnings on January 10, 2025 (EST) with actual revenue of USD 4.886 M and EPS of USD 0.0193

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

SBIO

NNNN

LABU

Anbio Biotechnology reported strong FY25 results with sales of $8.65M, up from $8.19M in 2024. Net income surged to $6.4M, and earnings per share increased to 15 cents. The company is diversifying away from COVID products, generating 80.4% of IVD revenue from non-COVID sources. New product launches include a dry chemiluminescence immunoassay and a 15-minute PCR system. Anbio aims for long-term growth in the expanding IVD market, projected to reach $157.63 billion by 2030. Shares rose 21.30% to $26.94 in the past month.

benzinga_article

ALPS Medical Breakthrough

SPDR S&P Health Equip

VanEck Biotech ETF

iShares Biotechnology ETF

iShares US Medical Devices

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

Anbio Biotechnology Posts Solid FY25 Results, Diversifies Portfolio

UNBX

International Biotechnology (LON:IBT) shares have crossed above their 200-day moving average, trading at GBX 895.01 with a market cap of £285.54 million. The stock has a P/E ratio of -272.04 and a beta of 0.43. Analysts currently hold a 'Hold' rating on the stock, but it is not recommended as a top buy compared to five other stocks identified by top-rated analysts.

Market Beat

Unity Biotechnology, Inc.

International Biotechnology (LON:IBT) Stock Price Crosses Above 200-Day Moving Average   - Time to Sell?

PMCB

Generate Biomedicines raised $400 million in its U.S. IPO, pricing shares at $16 each. The offering comes amid a volatile IPO market, influenced by concerns over AI's impact on industries. The company sold 25 million shares, backed by Flagship Pioneering, and will trade on Nasdaq under the ticker "GENB." Generate focuses on AI-driven drug discovery, with its lead candidate for severe asthma in late-stage trials, expected to complete enrollment by mid-2028. Underwriters include Goldman Sachs and Morgan Stanley.

fidelity

Morgan Stanley

PharmaCyte Biotech

GOLDMAN SACHS GROUP INC DEP REP 1/1000TH PRF D

GOLDMAN SACHS GROUP INC DEP SHR REP 1/1000TH PFD SER A

GOLDMAN SACHS GROUP INC DEP SHS REPSTG 1/1000TH PRF SER C

Drug developer Generate Biomedicines raises $400 million in US IPO

Generate Biomedicines, Inc. has announced the pricing of its initial public offering (IPO) of 25 million shares at $16.00 each, aiming for gross proceeds of $400 million. The shares will trade on the Nasdaq under the ticker symbol "GENB" starting February 27, 2026, with the offering expected to close on March 2, 2026. Goldman Sachs and Morgan Stanley are the lead managers for the offering. A registration statement has been filed with the SEC, and the offering is subject to customary closing conditions.

StockTitan

Proshares UltraShort Nasdaq Biotech

Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering | GENB Stock News

Generate Biomedicines, a biotech firm utilizing AI for drug development, plans to raise up to $425 million in an IPO. This move aligns with a resurgence in biotech listings, driven by increased investor interest in innovative healthcare solutions. The company's AI-driven approach aims to enhance drug discovery, positioning it as a key player in the biotech sector's growth. The IPO reflects Generate Biomedicines' ambition to expand operations and leverage the industry's momentum.

CoinLive

Biotech Firm Generate Biomedicines Plans $425 Million IPO Amid Sector Growth

Anbio Biotechnology(NNNN.US)

Anbio Biotechnology Posts Solid FY25 Results, Diversifies Portfolio

International Biotechnology (LON:IBT) Stock Price Crosses Above 200-Day Moving Average - Time to Sell?

Drug developer Generate Biomedicines raises $400 million in US IPO

Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering | GENB Stock News

Biotech Firm Generate Biomedicines Plans $425 Million IPO Amid Sector Growth